- Trials with a EudraCT protocol (12,693)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (1,156)
12,693 result(s) found for: placebo.
Displaying page 236 of 635.
EudraCT Number: 2020-002059-38 | Sponsor Protocol Number: APRIL | Start Date*: 2021-02-25 |
Sponsor Name:APTATARGETS S.L. | ||
Full Title: A Double-Blind, Placebo-Controlled, Randomized, Phase Ib/IIa Clinical Study of ApTOLL for the Treatment of Acute Ischemic Stroke | ||
Medical condition: Acute Ischemic Stroke (AIS) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) DE (Completed) PT (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-002324-32 | Sponsor Protocol Number: CLJN452D12201C | Start Date*: 2019-12-13 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: A randomized, double-blind, parallel-group, multicenter study to assess efficacy, safety, and tolerability of oral tropifexor (LJN452) & licogliflozin (LIK066) combination therapy, compared to each... | |||||||||||||
Medical condition: Non-alcoholic Steatohepatitis (NASH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Prematurely Ended) GB (GB - no longer in EU/EEA) ES (Prematurely Ended) DK (Prematurely Ended) IT (Prematurely Ended) SK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001526-59 | Sponsor Protocol Number: CL2-95011-001 | Start Date*: 2020-10-20 | |||||||||||
Sponsor Name:Institut de Recherches Internationales Servier | |||||||||||||
Full Title: A phase IIa efficacy and safety trial with intravenous S95011 in primary Sjögren’s Syndrome patients. An international, multicentre, randomised, double-blind, placebo-controlled study | |||||||||||||
Medical condition: Primary Sjögren’s Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) HU (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001364-38 | Sponsor Protocol Number: WN29922 | Start Date*: 2018-06-18 | ||||||||||||||||
Sponsor Name:Roche Farma S.A.(Soc. Unipersonal)que realiza el ensayo en España y que actúa como representante F.Hoffmann-La Roche LTD | ||||||||||||||||||
Full Title: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, PARALLEL-GROUP, EFFICACY, AND SAFETY STUDY OF GANTENERUMAB IN PATIENTS WITH EARLY (PRODROMAL TO MILD) ALZHEIMER'S DISEASE | ||||||||||||||||||
Medical condition: Alzheimer’s Disease (AD) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Prematurely Ended) BE (Completed) LT (Completed) DE (Completed) HU (Completed) DK (Completed) IT (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-003084-61 | Sponsor Protocol Number: CLEE011A2301 | Start Date*: 2014-01-24 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A randomized double-blind, placebo-controlled study of LEE011 in combination with letrozole for the treatment of postmenopausal women with hormone receptor positive, HER2-negative, advanced breast ... | |||||||||||||
Medical condition: HR+, HER2- advanced breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: AT (Completed) DE (Completed) CZ (Completed) ES (Completed) SE (Completed) NL (Completed) HU (Completed) FI (Completed) IE (Completed) BE (Completed) DK (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000722-26 | Sponsor Protocol Number: AVM-003-HC | Start Date*: 2021-01-11 | |||||||||||
Sponsor Name:AlloVir, Inc. | |||||||||||||
Full Title: Phase 3 Multicenter, Double-Blind, Placebo-Controlled Trial of Viralym-M (ALVR105) for the Treatment of Patients With Virus-Associated Hemorrhagic Cystitis After Allogeneic Hematopoietic Cell Trans... | |||||||||||||
Medical condition: Virus-Associated Hemorrhagic Cystitis After Allogeneic Hematopoietic Cell Transplant. | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) FR (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003688-23 | Sponsor Protocol Number: 20180109 | Start Date*: 2020-10-13 | |||||||||||
Sponsor Name:Amgen Inc. | |||||||||||||
Full Title: A Double-blind, Randomized, Placebo-controlled Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of AMG 890 (a GalNAc-conjugated Small Interfering RNA [siRNA]) in Subjects with Elevated ... | |||||||||||||
Medical condition: Cardiovascular Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) NL (Completed) IS (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003647-29 | Sponsor Protocol Number: SN-SPAS-202 | Start Date*: 2020-03-23 | |||||||||||
Sponsor Name:Solstice Neurosciences a wholly-owned subsidiary of US WorldMeds, LLC | |||||||||||||
Full Title: A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Single-Treatment Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Lower Limb Spasticity Followed by an Open-La... | |||||||||||||
Medical condition: Lower Limb Spasticity | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Prematurely Ended) CZ (Completed) PL (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002939-29 | Sponsor Protocol Number: NN9536-4734 | Start Date*: 2021-07-05 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: Efficacy and safety of subcutaneous semaglutide 2.4 mg once-weekly in subjects with obesity and prediabetes | |||||||||||||
Medical condition: Obesity | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) DK (Completed) ES (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004856-24 | Sponsor Protocol Number: AC220-A-U302 | Start Date*: 2016-09-02 | |||||||||||
Sponsor Name:Daiichi Sankyo, Inc. | |||||||||||||
Full Title: A Phase 3, Double-Blind, Placebo-controlled Study of Quizartinib Administered in Combination with Induction and Consolidation Chemotherapy, and Administered as Continuation Therapy in Subjects 18 t... | |||||||||||||
Medical condition: FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) (+) acute myeloid leukemia (AML) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) CZ (Completed) DE (Completed) HU (Completed) ES (Ongoing) RO (Ongoing) BE (Completed) PT (Completed) BG (Completed) HR (Completed) EE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003302-40 | Sponsor Protocol Number: WO40242 | Start Date*: 2018-04-10 | |||||||||||
Sponsor Name:F. Hoffman-La Roche Ltd. | |||||||||||||
Full Title: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) AS ADJUVANT THERAPY AFTER DEFINITIVE LOCAL THERAPY IN PATIENTS WITH HIGH-RISK LOCA... | |||||||||||||
Medical condition: Locally advanced squamous cell carcinoma of the head and neck (SCCHN) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA) PL (Completed) FR (Completed) BE (Completed) PT (Completed) HU (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-005034-36 | Sponsor Protocol Number: CIDPRIT | Start Date*: 2018-05-22 | |||||||||||||||||||||
Sponsor Name:IRCCS ISTITUTO CLINICO HUMANITAS | |||||||||||||||||||||||
Full Title: An Italian database-based randomized controlled trial with Rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) | |||||||||||||||||||||||
Medical condition: Chronic inflammatory demyelinating polyradiculoneuropathy | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IT (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003485-39 | Sponsor Protocol Number: NN7533-4470 | Start Date*: 2022-07-19 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: A multicentre trial evaluating the efficacy and safety of oral decitabine-tetrahydrouridine (NDec) in patients with sickle cell disease | |||||||||||||
Medical condition: Sickle cell disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003308-14 | Sponsor Protocol Number: Nef-301OLE | Start Date*: 2020-10-21 | |||||||||||
Sponsor Name:Calliditas Therapeutics AB | |||||||||||||
Full Title: An Open-Label Extension (OLE) Study to Evaluate the Efficacy and Safety of Nefecon Treatment in Patients With IgA Nephropathy Who Have Completed Study Nef-301 | |||||||||||||
Medical condition: Primary IgA nephropathy patients at risk of developing end stage renal disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) SE (Completed) PL (Completed) BE (Completed) FR (Completed) GB (GB - no longer in EU/EEA) GR (Completed) FI (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-000762-11 | Sponsor Protocol Number: 62113-55115 | Start Date*: 2014-10-20 | |||||||||||
Sponsor Name:European Organisation for Research and Treatment of Cancer (EORTC) | |||||||||||||
Full Title: A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in High Grade Undifferentiated Uterine Sarcoma (HGUS) after stabilization or response to doxoru... | |||||||||||||
Medical condition: High Grade Undifferentiated Uterine Sarcoma (HGUS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: BE (Completed) IT (Completed) ES (Completed) DE (Completed) GB (GB - no longer in EU/EEA) NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004108-33 | Sponsor Protocol Number: M20-262 | Start Date*: 2022-03-09 | |||||||||||
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | |||||||||||||
Full Title: A Phase 2 Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lutikizumab (ABT-981) in Adult Subjects with Moderate to Severe Hidradenitis Suppurat... | |||||||||||||
Medical condition: Hidradenitis Suppurativa | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) DE (Completed) GR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003824-35 | Sponsor Protocol Number: MK-7902-006 | Start Date*: 2019-05-02 | ||||||||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | ||||||||||||||||||
Full Title: A Phase 3 Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) with or without Lenvatinib (E7080/MK-7902) as Firs... | ||||||||||||||||||
Medical condition: Metastatic Nonsquamous Non-small Cell Lung Cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) ES (Completed) PL (Completed) FR (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002268-53 | Sponsor Protocol Number: 219288 | Start Date*: 2022-12-09 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Limited | |||||||||||||
Full Title: Phase 3 Multicenter, Randomized, Double-Blind, Study to Assess the Efficacy and Safety of Treatment with Bepirovirsen in HBeAg-negative Nucleos(t)ide Analogue-treated Participants with Chronic Hepa... | |||||||||||||
Medical condition: Chronic Hepatitis B infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) IT (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) DE (Ongoing) GR (Trial now transitioned) HU (Trial now transitioned) BG (Trial now transitioned) RO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002148-56 | Sponsor Protocol Number: ACT-CS-005 | Start Date*: 2021-07-22 | |||||||||||
Sponsor Name:ACTICOR BIOTECH | |||||||||||||
Full Title: A RANDOMIZED, DOUBLE BLIND, MULTICENTER, MULTINATIONAL, PLACEBO CONTROLLED, PARALLEL GROUP, SINGLE DOSE, ADAPTIVE EFFICACY AND SAFETY STUDY OF GLENZOCIMAB USED AS AN ADD-ON THERAPY ON TOP OF STANDA... | |||||||||||||
Medical condition: Acute ischemic stroke | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) DE (Completed) SK (Completed) ES (Ongoing) CZ (Completed) DK (Completed) BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004956-12 | Sponsor Protocol Number: CORT125134-456 | Start Date*: 2021-02-24 | |||||||||||
Sponsor Name:Corcept Therapeutics Incorporated | |||||||||||||
Full Title: Glucocorticoid Receptor Antagonism in the Treatment of Hypercortisolism in Patients with Cortisol-Secreting Adrenal Adenomas or Hyperplasia (GRADIENT): A Phase 3, Randomized, Double-Blind, Placebo-... | |||||||||||||
Medical condition: Hypercortisolism | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) PL (Completed) BG (Completed) IT (Completed) RO (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
• EEA CTAs: Date study was authorised to proceed
• Outside EU/EEA: Date study was submitted in EudraCT
• Outside EU/EEA: Date study was submitted in EudraCT
